Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of “Buy” from Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR) have received an average rating of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $11.36.

A number of equities research analysts have weighed in on VOR shares. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research note on Friday, November 8th. Barclays decreased their target price on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Robert W. Baird lowered their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research note on Friday, September 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research note on Friday, November 8th.

Vor Biopharma Stock Down 2.1 %

Shares of VOR opened at $0.80 on Friday. The stock’s 50-day moving average price is $0.77 and its 200 day moving average price is $0.99. The firm has a market capitalization of $54.94 million, a price-to-earnings ratio of -0.48 and a beta of -0.40. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $3.14.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, hitting the consensus estimate of ($0.40). Equities research analysts expect that Vor Biopharma will post -1.55 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of VOR. Vanguard Group Inc. grew its holdings in Vor Biopharma by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after acquiring an additional 69,436 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Vor Biopharma by 48.0% in the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after purchasing an additional 160,642 shares in the last quarter. Exchange Traded Concepts LLC raised its position in Vor Biopharma by 40.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after purchasing an additional 48,017 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after buying an additional 27,597 shares in the last quarter. Finally, Rosalind Advisors Inc. bought a new position in Vor Biopharma in the 3rd quarter valued at $54,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.